In this edition of our Inside Global Pharma podcast series, Jennifer Curtis connects with Josh Hattem to discuss trends in oncology portfolio strategy, building on a previous episode, “The value of focus.”

Highlights from the episode:

• The oncology therapy area’s future is not as certain as it was in the past; blockbuster launches sold 47% higher on average in 2012-2016 compared to 2017-2021
• A range of factors contributed to this drop, including intense competition, smaller, more fragmented opportunities and the entrance of emerging pharma players into the space
• The latest ZS research suggests intentional use of the customer lens early in portfolio strategy development could help companies “win” in oncology by enhancing “share of mind”